Our clinical-stage lead candidate, EL-22,
activates the body’s own immune system to inhibit myostatin, a negative regulator of muscle growth.
Data
suggests that blocking myostatin causes muscle cell growth and increases muscle power. Combining this muscle targeting approach with existing GLP-1 therapies for weight-loss could have significant promise and a lasting impact in helping obese patients lose fat, while preserving lean muscle mass.
